Arrowhead's third-generation RNAi shows initial efficacy against HBV

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) reported initial data showing that monthly doses of its third-generation RNAi therapy ARO-HBV reduced circulating hepatitis B surface antigen (HBsAg) levels in a broad population of patients with chronic HBV infection.

The data were from eight patients that

Read the full 413 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE